更新于：2024-12-31
Betahistine Hydrochloride
盐酸倍他司汀
更新于：2024-12-31
概要
基本信息
原研机构- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1966-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C8H13ClN2 |
InChIKeyPIIWYFURBFSHKM-UHFFFAOYSA-N |
CAS号5579-84-0 |
关联
58
项与 盐酸倍他司汀 相关的临床试验盐酸倍他司汀片人体生物等效性研究
盐酸倍他司汀片（8mg）在中国成年健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、交叉生物等效性试验
盐酸倍他司汀片（8mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸倍他司汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸倍他司汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸倍他司汀 相关的专利（医药）
登录后查看更多信息
651
项与 盐酸倍他司汀 相关的文献（医药）2024-12-01SLEEP MEDICINE
Signal detection of drugs associated with obstructive and central sleep apnoea
Article
作者: Hlavaty, A ; Joyeux-Faure, M ; Khouri, C. ; Jambon-Barbara, C. ; Hlavaty, A. ; Pepin, J L ; Borel, J C ; Cracowski, J.L. ; Khouri, C ; Pepin, J.L. ; Revol, B ; Cracowski, J L ; Joyeux-Faure, M. ; Borel, J.C. ; Revol, B. ; Jambon-Barbara, C
We aim to discover new safety signals of drug-induced sleep apnoea (SA), a global health problem affecting approximately 1 billion people worldwide. We first conducted a series of sequence symmetry analyses (SSA) in a cohort composed from all patients who received a first SA diagnosis or treatment between 2006 and 2018 in the Echantillon Généraliste des Bénéficaires (EGB), a random sample of the French healthcare database. We used two primary outcomes to estimate the sequence ratio (SR) for all drug classes available in France: a sensitive one (diagnosis or treatment of SA) and a specific one (Positive Airway Pressure (PAP) therapy). We then performed disproportionality analyses using the "Bayesian neural network method" on all cases of sleep apnoea (MedDRA high level term) reported up to November 2023 in the World Health Organisation (WHO) pharmacovigilance database. Among the 728,167 individuals, 46,193 had an incident diagnosis or treatment for SA and 17,080 had started an incident treatment by PAP therapy. Fifty-eight drug classes had a significant SR, with 7 considered highly plausible: opium alkaloids and derivatives, benzodiazepine derivatives, other centrally acting agents, other anxiolytics, carbamic acid esters, quinine and derivatives and antivertigo preparations; with consistent signals found for the first 3 drug classes in the disproportionality analysis. In this signal detection study, we found that opioids, benzodiazepines (but not Z-drugs) and myorelaxing agents are associated with the onset or aggravation of SA. Moreover, a new safety signal for antivertigo preparations such as betahistine emerged and needs to be further explored.
2024-12-01Laryngoscope Investigative Otolaryngology
Effect of betahistine on pro‐inflammatory cytokine expression in autoimmune inner ear disease and Meniere's disease patients
Article
作者: Yellin, Ilana ; Pathak, Shresh ; Vambutas, Andrea
Abstract:
Objective:
Betahistine is a partial H1 receptor agonist and a potent H3 receptor antagonist commonly used for the treatment of MD and peripheral vertigo. The aim of this study was to investigate the impact of betahistine on the salt induced cytokine expression profiles of AIED and MD patients.
Methods:
Peripheral blood mononuclear cells (PBMCs) were obtained from 24 patients with autoimmune inner ear disease (AIED) or Meniere's disease (MD) during an acute exacerbation of hearing loss. These PBMCs were cultured with 80 mM NaCl or a combination of 80 mM NaCl and betahistine and IL‐1β and IL‐6 expression were measured by real time PCR and ELISA.
Results:
In most patients, IL‐1β expression in response to NaCl exceeded the unstimulated condition and this expression was abrogated by the addition of betahistine, which was statistically significant at p = .004. mRNA expression of IL‐1β was not reduced when samples were treated with both salt and betahistine compared to samples treated with salt alone, inferring the mechanism of betahistine‐mediated IL‐1β suppression is post‐translational. Similarly, IL‐6 cellular release was augmented with salt exposure and reduced with co‐culture of betahistine. Unlike IL‐1 however, betahistine appeared to reduce IL‐6 mRNA expression.
Conclusion:
We observe that betahistine abrogates salt‐induced IL‐1β expression, suggesting an additional treatment option for AIED and MD patients with inflammatory mediated disease.
Level of evidence:
Level 4.
2024-11-01ENT-EAR NOSE & THROAT JOURNAL
Which Canal BPPV Should be Checked for Residual Disease after 1 Week?
Article
作者: Öner, Fatih
Objectives: The study aimed to determine the residual disease rate due to the affected canal in patients diagnosed with benign paroxysmal positional vertigo (BPPV) and reveal the factors affecting the residual disease. Materials and Methods: A comprehensive investigation was conducted to determine the effect of the affected canal, sociodemographic data, body mass index, hospital admission time, systemic disease history, betahistine use, and previous otologic vertigo history on the residual BPPV rate. This investigation was carried out on 201 patients who underwent repositioning maneuvers with BPPV diagnosis and came for a follow-up 1 week later, ensuring a robust and reliable dataset. Results: Two hundred one patients were included in the study: 91 (45.3%) male and 110 (54.7%) female. The mean age of the patients was 60.44 + 13.83 (min = 23-max = 90) years. Residual disease was significantly higher in bilateral canal involvement ( P = .001), anterior canal involvement, and those presenting 72 hours after the onset of the vertigo attack ( P = .001). There was no significant difference between residual disease and those with successful initial maneuver results regarding age, gender, obesity, canalolithiasis, or cupulolithiasis. Conclusion: The most effective treatment for BPPV is canalith reposition maneuvers. We recommend that patients be called for follow-up after 1 week, especially in cases of anterior canal involvement and bilateral involvement. These findings provide valuable insights for the management of BPPV.
100 项与 盐酸倍他司汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉硬化 | 中国 | 1984-01-01 | |
| 脑血管疾病 | 中国 | 1984-01-01 | |
| 耳鸣 | 中国 | 1984-01-01 | |
| 眩晕 | 中国 | 1984-01-01 | |
| 梅尼埃病 | 美国 | - | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高胆固醇血症 | 临床2期 | 以色列 | 2007-05-01 | |
| 体重增加 | 临床2期 | 加拿大 | 2007-03-01 | |
| 体重增加 | 临床2期 | 以色列 | 2007-03-01 | |
| 肥胖 | 临床2期 | 美国 | 2007-01-01 | |
| 前庭疾病 | 临床申请 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 梅尼埃病 一线 | 15 | Betahistine alone (24 mg) | 構蓋襯艱膚網選鏇積遞(襯鹽憲壓鬱願壓網憲顧) = 遞糧夢蓋壓淵鏇繭製獵 製齋範淵憲築網簾願鬱 (艱窪艱壓範顧醖齋鏇窪, +/ ~ 0.47) | 积极 | 2023-01-01 | |
Betahistine alone (48 mg) | 構蓋襯艱膚網選鏇積遞(襯鹽憲壓鬱願壓網憲顧) = 艱淵鏇選顧築築醖鏇簾 製齋範淵憲築網簾願鬱 (艱窪艱壓範顧醖齋鏇窪, +/ ~ 0.47) | ||||||
临床4期 | 124 | (Divaza) | 襯醖製憲積壓艱遞網選(憲壓築鹽糧製遞遞淵簾) = 簾醖鬱窪餘範醖範鹹鑰 鬱齋網壓襯範獵鏇淵鹽 (觸糧襯鑰鑰夢壓襯廠築, 糧餘願鏇糧繭鹹衊鹽獵 ~ 鬱齋鹹廠夢範糧壓壓鬱) 更多 | - | 2021-08-26 | ||
Placebo (Placebo) | 襯醖製憲積壓艱遞網選(憲壓築鹽糧製遞遞淵簾) = 鏇積觸壓窪窪鹽糧餘願 鬱齋網壓襯範獵鏇淵鹽 (觸糧襯鑰鑰夢壓襯廠築, 繭製網窪餘製積艱窪窪 ~ 餘壓餘憲繭餘襯壓廠網) 更多 | ||||||
临床2期 | 48 | (Betahistine) | 願範艱築醖醖鏇淵壓遞(鑰鬱築積窪願鏇築範選) = 範觸夢築顧衊鹹選衊憲 壓壓齋衊鏇構選壓獵廠 (窪夢蓋壓蓋鏇醖鏇簾獵, 築顧觸遞選繭鹹齋淵壓 ~ 鬱膚顧繭遞鬱觸齋選遞) 更多 | - | 2019-01-25 | ||
placebo (Placebo) | 願範艱築醖醖鏇淵壓遞(鑰鬱築積窪願鏇築範選) = 夢夢齋積齋襯網夢淵餘 壓壓齋衊鏇構選壓獵廠 (窪夢蓋壓蓋鏇醖鏇簾獵, 觸蓋壓蓋襯衊鑰糧鹽襯 ~ 艱觸構鑰窪窪鹹構選襯) 更多 | ||||||
N/A | - | Betahistine dihydrochloride 48 mg | 鑰範淵衊壓憲齋繭衊艱(醖遞願製夢簾廠憲選構) = 膚憲鏇築構壓襯艱夢淵 網廠餘艱製齋遞窪範鬱 (壓鬱襯鏇鏇願鑰膚積範 ) 更多 | 积极 | 2003-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用